{
  "protocolSection": {
    "identificationModule": {
      "nctId": "NCT05167617",
      "orgStudyIdInfo": {
        "id": "34960/10/21"
      },
      "organization": {
        "fullName": "Tanta University",
        "class": "OTHER"
      },
      "briefTitle": "Vitamin D Improves Clinical Manifestations in Asthmatic Children",
      "officialTitle": "Vitamin D Supplemental Therapy for Asthmatic Children May Improve Clinical Manifestations and Reduce IgE Serum Levels"
    },
    "statusModule": {
      "statusVerifiedDate": "2021-12",
      "overallStatus": "COMPLETED",
      "expandedAccessInfo": {
        "hasExpandedAccess": false
      },
      "startDateStruct": {
        "date": "2020-06-01",
        "type": "ACTUAL"
      },
      "primaryCompletionDateStruct": {
        "date": "2021-07-21",
        "type": "ACTUAL"
      },
      "completionDateStruct": {
        "date": "2021-09-15",
        "type": "ACTUAL"
      },
      "studyFirstSubmitDate": "2021-11-21",
      "studyFirstSubmitQcDate": "2021-12-09",
      "studyFirstPostDateStruct": {
        "date": "2021-12-22",
        "type": "ACTUAL"
      },
      "lastUpdateSubmitDate": "2021-12-09",
      "lastUpdatePostDateStruct": {
        "date": "2021-12-22",
        "type": "ACTUAL"
      }
    },
    "sponsorCollaboratorsModule": {
      "responsibleParty": {
        "type": "PRINCIPAL_INVESTIGATOR",
        "investigatorFullName": "Mohamed B.Hamza",
        "investigatorTitle": "Clinical Professor",
        "investigatorAffiliation": "Tanta University"
      },
      "leadSponsor": {
        "name": "Tanta University",
        "class": "OTHER"
      }
    },
    "oversightModule": {
      "isFdaRegulatedDrug": false,
      "isFdaRegulatedDevice": false,
      "isUsExport": false
    },
    "descriptionModule": {
      "briefSummary": "Objectives: Evaluation of the effect of vitamin D supplemental therapy (VDST) on clinical manifestation of bronchial asthma (BA) as judged by The International Study of Asthma and Allergies in Childhood (ISAAC) questionnaire and estimated serum levels of immunoglobulin E (IgE).\n\nPatients \\& Methods: scores of ISAAC questionnaire and blood samples were obtained for estimation of serum IgE and 25-hydroxy VD (25-HVD) at booking time (T1) of 102 BA patients. VDST was provided as 2000 IU daily for 3 and 6 months for patients had moderate and mild HVD, respectively. At the end of 12-m after start of VDST (T2), ISAAC questionnaire and serum levels of 25-HVD and IgE were re-evaluated and the percentage of change was calculated."
    },
    "conditionsModule": {
      "conditions": [
        "Asthma in Children"
      ]
    },
    "designModule": {
      "studyType": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "designInfo": {
        "allocation": "NA",
        "interventionModel": "SINGLE_GROUP",
        "primaryPurpose": "SUPPORTIVE_CARE",
        "maskingInfo": {
          "masking": "NONE"
        }
      },
      "enrollmentInfo": {
        "count": 102,
        "type": "ACTUAL"
      }
    },
    "armsInterventionsModule": {
      "armGroups": [
        {
          "label": "Vitamin Deficiency",
          "type": "EXPERIMENTAL",
          "interventionNames": [
            "Drug: Vit D"
          ]
        }
      ],
      "interventions": [
        {
          "type": "DRUG",
          "name": "Vit D",
          "description": "Vit D was provided as 2000 IU daily for 3 and 6 months for patients who had mild and moderate HVD, respectively.",
          "armGroupLabels": [
            "Vitamin Deficiency"
          ]
        }
      ]
    },
    "outcomesModule": {
      "primaryOutcomes": [
        {
          "measure": "Clinical Improvement",
          "description": "The effect of vitamin D supplemental therapy on pediatric asthma severity as judged by the score of ISSAC questionnaire.",
          "timeFrame": "3 to 6 months"
        }
      ]
    },
    "eligibilityModule": {
      "eligibilityCriteria": "Inclusion Criteria:\n\n* Patients in the age group of 6-14 years, free of exclusion criteria and complaining of chest wheezes were included in the study.\n\nExclusion Criteria:\n\n* Presence of acute asthmatic attack, current or recurrent chest infection, allergic dermatological disorders, chronic rhino-sinusitis, deviated nasal septum, other nasal or palatal congenital anomalies, history of chronic exposure to allergens, or living in areas characterized by air pollution, being passive smokers since birth, presence of autoimmune disorders, serum 25-HVD \\>50 nmol/L and presence of clinically evident HVD.",
      "healthyVolunteers": false,
      "sex": "ALL",
      "minimumAge": "6 Years",
      "maximumAge": "14 Years",
      "stdAges": [
        "CHILD"
      ]
    },
    "contactsLocationsModule": {
      "locations": [
        {
          "facility": "Tanta university",
          "city": "Tanta",
          "country": "Egypt",
          "geoPoint": {
            "lat": 30.78847,
            "lon": 31.00192
          }
        }
      ]
    },
    "ipdSharingStatementModule": {
      "ipdSharing": "NO"
    }
  },
  "derivedSection": {
    "miscInfoModule": {
      "versionHolder": "2026-02-04"
    }
  },
  "hasResults": false
}